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Background and purpose: Due to the long life expectancy after treatment, the risk of late effects after
radiotherapy (RT) is of particular importance for patients with Hodgkin lymphoma (HL). Both deep inspi-
ration breath hold (DIBH) and proton therapy have been shown to reduce the dose to normal tissues for
mediastinal HL, but the impact of these techniques in combination is unknown. The purpose of this study
was to compare the life years lost (LYL) attributable to late effects after RT for mediastinal HL using inten-
sity modulated radiation therapy (IMRT) in free breathing (FB) and DIBH, and proton therapy in FB and
DIBH.
Materials and methods: Plans for each technique were created for 22 patients with HL. Doses were
extracted and the risk of late effects and LYL were estimated.
Results: We found that the use of DIBH, proton therapy, and the combination significantly reduced the
LYL compared to IMRT in FB. The lowest LYL was found for proton therapy in DIBH. However, when
IMRT in DIBH was compared to proton therapy in FB, no significant difference was found.
Conclusions: Patient-specific plan comparisons should be used to select the optimal technique when
comparing IMRT in DIBH and proton therapy in FB.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 125 (2017) 41–47 This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).The majority of patients diagnosed with Hodgkin lymphoma
(HL) have a long life expectancy following treatment. HL accounts
for 12% of cancers in the 15–29-year age group [1], and treatment
is highly effective with a 5-year relative survival rate of 93.1% for
regional disease [2]. Consequently, HL survivors have a long time
span in which they are at risk of developing late effects of treat-
ment such as second cancers and cardiovascular disease [3], and
it has been shown that RT contributes to that risk [4–6]. Therefore,
it is important to minimize these risks for HL patients whenever
possible.
Both deep inspiration breath hold (DIBH) and proton therapy
have been shown to reduce the dose to normal tissues for HL
patients with mediastinal disease [7–12]; however, to the authors’
knowledge, the impact of these techniques relative to each other orin combination has not been studied. An understanding of which of
these has the largest impact on the risk of late effects would enable
clinicians to prioritize between techniques, especially if the combi-
nation is not available.
Dose-effect models based on epidemiological data can be
employed to estimate the risk of late effects from modern treat-
ments. While such models have large uncertainty, they can be used
as a tool in the context of comparative analysis of different treat-
ment options. Our group has developed a method of risk modeling
that converts organ at risk (OAR) dose into an estimated life years
lost (LYL) from various possible late effects [13]. In this way, the
severity of different late effects can be placed on a common scale
for direct comparison.
In this study, we propose to investigate and compare the LYL
from late effects of RT for HL with mediastinal involvement using
intensity modulated radiation therapy (IMRT) in free breathing
(FB) and in DIBH, and proton therapy in FB and in DIBH.
42 Late effects after protons/DIBH for HLMaterial and methods
Patients
22 patients with early-stage HL were enrolled in a previous
prospective protocol to investigate the benefits of DIBH, described
elsewhere [12,14]. In summary, the study included pre-
chemotherapy positron emission tomography/computed tomogra-
phy (PET/CT) scans and planning CT scans both in FB and in DIBH.
Contouring was completed on both the FB and DIBH scans to define
the CTV by the involved node technique [15]. Treatment plans
were created on both scans, and the patients were treated with
photons in either FB or DIBH, whichever was more clinically appro-
priate for the patient. This protocol was approved by the regional
ethics committee for Copenhagen H-D-2007-0069.Treatment planning
For the present retrospective study, four treatment plans were
generated for each patient: IMRT in FB, IMRT in DIBH, proton ther-
apy in FB, and proton therapy in DIBH. The prescription dose was
30.6 Gy in 17 fractions to the initially involved volume following
the International Lymphoma Radiation Oncology Group (ILROG)
guidelines [15]. Proton therapy doses were in Gy (RBE) (relative
biological equivalent) assuming an RBE of 1.1 for protons [16],
and 1 for photons. All plans were created using the Eclipse treat-
ment planning system (photons: AAA version 10, protons: PCS ver-
sion 13, Varian Medical Systems, Palo Alto, USA; proton beam data
from Skandionkliniken, Uppsala, Sweden).
IMRT plans were created in accordance with the clinical proce-
dure at Rigshospitalet, Copenhagen, Denmark [15]. For plans in FB,
the CTV-to-PTV margins were 1.5 cm in the superior-inferior direc-
tion in the mediastinum, and 1 cm in other directions. For plans in
DIBH, the CTV-to-PTV margins were 1 cm in all directions. The
number of fields varied between 4 and 7, with 5 fields being the
most common configuration. Whenever possible, fields were posi-
tioned to minimize entrance dose through the OARs (heart, lungs,
and breasts). In general, 6 MV energy was used, with occasional
use of 18 MV for supplementary fields.
Proton plans were created at Rigshospitalet with guidance
from the experienced investigators at MD Anderson Cancer Cen-
ter. Pencil beam scanning with an anterior-posterior and
posterior-anterior beam arrangement was used for all patients.
Beam-specific range uncertainties were calculated as 3.5% of the
range to the distal edge of the CTV plus 3 mm. In cases where
the beam-specific range uncertainties were less than the CTV-
to-PTV margins used for IMRT planning, the same PTV was used
as was used for IMRT planning (1.5 cm superior/inferior and
1 cm otherwise for FB and 1 cm for DIBH). For five patients, the
range uncertainties for the posterior beam calculated with the
formula above were 1–2 mm greater than the CTV-to-PTV mar-
gins that were used for IMRT planning in the anterior direction.
For these patients, the PTV was expanded an additional 1–2 mm
in the anterior direction to encompass the range uncertainty.
For most patients, single-field optimization was used. For five
patients with involved nodes surrounding the heart, multi-field
optimization (intensity modulated proton therapy (IMPT)) was
used to reduce dose to the heart.
During treatment planning for both IMRT and proton plans,
the clinical priorities in order of highest to lowest were 1) target
coverage, 2) reduction of the mean dose to the heart and lungs,
and 3) reduction of the mean dose to the breasts (females). Addi-
tional objectives were used during optimization as needed for
each patient to reduce the dose to normal tissues as much as
possible.Dosimetric analysis
Dosimetric data for the target and OARs were extracted for all
plans. Specifically, the conformity index (CI; volume of body
receiving 95% of prescription dose divided by volume of the PTV)
and homogeneity index (HI; maximum dose in the PTV divided
by the prescription dose) for the PTV were extracted as a measure
of coverage of the target. The mean dose was extracted for the
heart, heart valves, left anterior descending coronary artery
(LADCA), lungs, and breasts (females). For proton plans, neutron
doses were added to the therapeutic doses using measured data
by Schneider et al. 2002 following the methods of Cella et al.
2013. 6  1014 Sv/proton and 1011 protons per Gy (RBE) of thera-
peutic dose were assumed [17,18]. This corresponds to the neutron
dose equivalent in the region of the target, but it was applied to the
OARs since all OARs considered in this study were adjacent to or
overlapping with the target. Cumulative dose-volume histograms
(DVHs) were exported for the heart and lung, neutron dose added
to the proton plans, and mean DVHs for all patients for each treat-
ment technique were calculated.
To estimate the effect of uncertainties in positioning and CT cal-
ibration on the dose, robustness analysis was performed by calcu-
lating the plan uncertainty doses using the built-in tool in the
treatment planning system. A positioning uncertainty of 5 mm
for both IMRT and proton therapy and Hounsfield Unit (HU) uncer-
tainty of 3.5% for proton therapy were assumed. These uncertainty
doses represent ‘worst case’ scenarios, not an estimation of the
actual delivered dose.Hazard ratios
Hazard ratios (HRs) per Gy relative to the unirradiated popula-
tion were estimated from the literature for various late effects. The
hazard ratios of heart failure [19], myocardial infarction [19],
valvular heart disease [20], lung cancer [21], and breast cancer
[22] (females) were estimated. Most risk models displayed a linear
dose–response relationship and as such, the mean dose to the
respective organ was used. An exception was valvular heart dis-
ease, where the equivalent dose in 2 Gy fractions (calculated from
the differential DVH) to either the mitral valve or the aortic valve,
whichever received the higher dose, was used in the risk calcula-
tion [20] (personal communication with Dr. Cutter). The risk mod-
els used are listed in Table S1.Life years lost calculation
To convert doses to an estimation of the impact of the late
effects on life expectancy after treatment, the LYL was calculated
for each plan [13]. The LYL is the estimated reduction in life expec-
tancy attributable to late effects from RT, and takes into account
the age at exposure, the patient’s sex, and the prognosis of the pos-
sible late effects [23–25]. The endpoints included in the LYL were
heart failure, myocardial infarction, valvular heart disease, lung
cancer, and breast cancer (females). Calculations were performed
in Matlab (version 2016b, The MathWorks, Inc, Natick, MA) using
the risk models in Table S1 and the methodology and formulae
in Brodin et al. [13] to integrate over attained age and account
for mortality after an acquired late effect.Statistical analysis
The Friedman test was used for the dosimetric and risk metrics,
with post-hoc two-sided pairwise analysis using Bonferroni correc-
tion and p-values <0.05 were considered significant. All statistical
analyses were performed in Matlab.
Fig. 2. Mean cumulative dose-volume histograms (DVHs) for the heart for intensity
modulated radiation therapy (IMRT) in free breathing (FB), IMRT in deep inspiration
breath hold (DIBH), proton therapy in FB, and proton therapy in DIBH for the 22
patients studied.
L.A. Rechner et al. / Radiotherapy and Oncology 125 (2017) 41–47 43Results
Four plans were created for each patient, resulting in a total of
88 plans. Example treatment plans for each technique for a repre-
sentative patient are shown in Fig. 1. Mean DVHs for the heart and
lung are plotted in Figs. 2 and 3, the individual DVHs for each
patient can be found in the supplementary material (Figs. S1 and
S2). The HI and CI values were considered clinically equivalent
for all plans (Table S2). All plans were considered to be robust with
respect to positioning and range uncertainties (Table S3).
DIBH reduced the dose to cardiovascular structures compared
to FB, regardless of whether proton therapy or IMRT was used
(Table 1). This benefit was especially observed for the heart valves,
where DIBH led to a median dose reduction of 4.7 Gy for IMRT and
2.3 Gy for proton therapy.
DIBH also reduced the mean dose to the lungs by 2.3 Gy for
IMRT and 1.2 Gy for proton therapy, although the difference for
proton therapy was not statistically significant. Nevertheless, the
lowest mean dose to the lungs was found with proton therapy in
DIBH, with a reduction of 4.6 Gy relative to IMRT in FB. ProtonFig. 1. Coronal images of treatment plans for each treatment technique for a representative patient: intensity modulated radiation therapy (IMRT) in free breathing (FB) (top
left), IMRT in deep inspiration breath hold (DIBH) (top right), proton therapy in FB (bottom left), proton therapy in DIBH (bottom right). The contours shown are the body
(green), CTV (pink), PTV (cyan), lungs (blue), heart (yellow), and heart valves (yellow).
Fig. 3. Mean cumulative dose-volume histograms (DVHs) for the lungs for intensity
modulated radiation therapy (IMRT) in free breathing (FB), IMRT in deep inspiration
breath hold (DIBH), proton therapy in FB, and proton therapy in DIBH for the 22
patients studied.
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44 Late effects after protons/DIBH for HLtherapy reduced the mean lung dose, but no statistically significant
difference was observed between proton therapy in FB and IMRT in
DIBH.
In contrast, a significant reduction in mean breast dose of about
3 Gy was found when proton therapy was used compared to IMRT,
with or without DIBH.
As most of the risk models used in this study displayed linear
dose–response relationships, HR followed the same trend as the
mean dose measures (Table 2). The risk of breast cancer was signif-
icantly reduced using proton therapy in FB compared to IMRT in
DIBH. However, for lung cancer and heart-related risks, no statisti-
cally significant difference in HR was seen when proton therapy in
FB or DIBH was compared to IMRT in DIBH.
When compared with IMRT in FB, the addition of DIBH and pro-
ton therapy, alone or in combination, significantly reduced the LYL,
and the lowest LYL from treatment was found for proton therapy in
DIBH. However, when proton therapy in FB was compared with
IMRT in DIBH, and when proton therapy in DIBH was compared
to proton therapy in FB, no significant differences in LYL were
found.
The total LYL was either dominated by lung cancer or valvular
heart disease for all patients, with the LYL from valvular heart dis-
ease being highly variable between patients and techniques. The
median LYL (range) for all plans was 0.33 (0.03–1.07) years from
lung cancer and 0.46 (0.002–5.35) years from valvular heart dis-
ease. The median dose (range) to the aortic or mitral valve was
26.8 (16.3–31.3) Gy for plans where valvular heart disease caused
greater than 1 year of LYL. The details of the LYL by cause are
shown in Fig. 4 for two representative patients (both had approx-
imately median-sized PTVs of about 1000 cc (range: 123–1943 cc
for all patients)). The LYL per technique per patient with 95% con-
fidence intervals are shown in Figs. S9–S13.Ta
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In this study, we investigated the impact of DIBH and proton
therapy, individually and in combination, in a cohort of patients
with mediastinal HL. Our study suggests that if only IMRT is avail-
able, IMRT in DIBH is superior to IMRT in FB with respect to the risk
of late effects. If both IMRT and proton therapy are available in
DIBH, our study suggests that proton therapy in DIBH is superior
to IMRT in DIBH and FB. If DIBH is available to the patient in com-
bination with IMRT but not with proton therapy, our study did not
find any statistically significant difference in the LYL over the
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Fig. 4. Life years lost (LYL) by cause for two representative patients: patient 4
(female) and patient 10 (male) for each approach. Mean doses to organs at risk for
these two patients are given in supplementary Table S4. Abbreviations: IMRT:
intensity modulated radiation therapy; FB (free breathing); DIBH (deep inspiration
breath hold).
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comparative planning would be required to determine the optimal
technique. Our study did not find a statistically significant differ-
ence when proton therapy in FB was compared with proton ther-
apy in DIBH; however, proton therapy in DIBH did result in the
lowest estimated LYL, and, unlike proton therapy in FB, a signifi-
cant difference was seen when proton therapy in DIBH was com-
pared to IMRT in DIBH.
An earlier study was reported by Cella et al. [18] comparing
photon and proton techniques for a patient with HL, without con-
sidering DIBH. In their study, the relative risk (RR) of second can-
cers was estimated after mediastinal RT for conventional RT
compared to various intensity modulated photon radiotherapies
and proton therapy. They also found a reduction in both breast
and lung cancer risk when proton therapy was compared to IMRT,
similar to our results.
Toltz et al. [26] also found a reduced risk of breast and lung can-
cer for proton therapy in FB relative to IMRT in FB in the form of
helical tomotherapy for mediastinal HL for 20 patients. However,
unlike our study, they did not find a reduction in cardiac mortality
between the two techniques. This could in part be due to differ-
ences in the choice risk model, which predicted very small excess
absolute risks of cardiac toxicity (median of 0.05% for both
tomotherapy and proton therapy) in their study.
One strength of the present study is that we have included the
most advanced techniques available for this patient group. Plans
were created using the involved node technique, contoured using
pre-chemotherapy PET/CT acquired in the treatment position in
both FB and DIBH, with and planned with pencil beam scanning
for the proton plans. Furthermore, we compared different combi-
nations of advanced treatment techniques, so the optimal solution
can be selected depending on which techniques are available for
the patient. Though DIBH is gaining acceptance in this patient
46 Late effects after protons/DIBH for HLgroup [10,27], it is rarely available in combination with proton
therapy. Hence, when referring a patient with HL for advanced
RT, the most likely treatment alternatives will be IMRT in DIBH
or proton therapy in FB.
Photon RT is constantly evolving. Alternative photon tech-
niques, such as the butterfly technique, which could reduce the
low dose bath at the expense of a slight decrease in conformity
[28], have gained interest [29,30]. One advantage of reducing
the low-dose bath is that recently published data have found that
low doses to the lung, such as the volume of lung receiving 5 Gy
or more (V5) or mean lung dose of >13.5 Gy, can be important for
the risk of radiation pneumonitis [31]. However, the treatment
planning in the present study was completed without specific
attention to the volume of tissue receiving a low dose of radia-
tion. Therefore, we think that future work could be done investi-
gating this type of photon planning and as compared to proton
planning.
Margins from the CTV-to-PTV have been shown to affect both
the dose to normal tissue and the risk of late effects [32]. The mar-
gins used in this study were based on the recommendations from
ILROG [15]. However, with the availability of daily online image
guidance, these might be reduced [33]. More research into optimal
margins for photons and protons, possibility in combination with
proton plans optimized for robustness, is warranted.
A limitation of the present study is that FB plans were generated
on FB CT datasets without four-dimensional CT information. It
should be noted that the interplay of motion and plan delivery
could affect the proton plans more than the photon plans. This
has been investigated by Zeng et al. [34] for 7 patients with medi-
astinal lymphoma, who found that when averaged over 17 frac-
tions, the proton dose to 98% of the internal target volume was
degraded less than 2%.
Additionally, the assumptions made in this work could affect
the conclusion. While the risk models were selected to be as appro-
priate as possible, very large uncertainty remains (Figs. S9–S13). In
addition, the majority of risk models used in this study were
adjusted for smoking status, and therefore estimate the risk asso-
ciated with increasing dose of radiation independent of the effect
of smoking (except for the risk model for breast cancer, where
smoking status was not taken into account [22]). While these
issues would limit the ability to accurately and precisely estimate
the risk for an individual patient, the focus of this study was on rel-
ative comparisons of techniques and not absolute risk calculations
for individual patients. Another assumption of this work was that
the RBE for proton therapy is a constant value of 1.1, without
any adjustment for the possibility of a higher RBE at the distal
end [35]. A higher RBE for proton therapy would effectively
increase the dose in that region, but detailed modeling of proton
RBE is still very uncertain and was beyond the scope of this work.
In summary, as with all modeling studies, the results and conclu-
sions of this work should be interpreted within the context of
the assumptions and limitations made in this study.
Furthermore, the LYL calculations in the present study only con-
sider mortality, but morbidity is also a major concern for patients’
quality of life. However, weighting of morbidities to a common
scale is challenging, and beyond the scope of the current work. Cor-
respondingly, another future application of this method could be to
extend model-based selection schemes for proton therapy such as
the models proposed by Langendijk et al. [36,37].
Finally, it should be noted that the results from this study are
simulated from risk models and the plans were created in the con-
text of a retrospective plan comparison study. Randomized trials
are the golden standard of medical evidence, but for assessment
of late effects, the challenge is that such a trial would require
10–15 years follow-up. Hence, modeling studies are needed to
guide current treatments.Conflicts of interest statement
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